GGHC
VIR icon

Gilder Gagnon Howe & Co’s Vir Biotechnology VIR Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-54,034
Closed -$1.85M – 353
2020
Q3 		$1.85M Buy
+54,034
New +$2.33M 0.01% 244

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Gilder Gagnon Howe & Co's VIR Position: Q4 2020 in Review

Gilder Gagnon Howe & Co sold out of Vir Biotechnology (VIR) in Q4 2020, closing a stake of 54,034 shares — an estimated $1.85M sold.

Gilder Gagnon Howe & Co first reported a position in VIR in Q3 2020 and held it in 1 quarter. The position peaked at $1.85M in Q3 2020. 143 funds tracked by Wall St. Rank hold VIR as of Q4 2020.

  • Gilder Gagnon Howe & Co reported no remaining Vir Biotechnology position as of Q4 2020 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 54,034 Vir Biotechnology shares in Q4 2020, an estimated $1.85M.
  • Gilder Gagnon Howe & Co first reported a position in Vir Biotechnology in Q3 2020 and held it in 1 quarter.
  • Gilder Gagnon Howe & Co's Vir Biotechnology position peaked at $1.85M in Q3 2020.
  • 143 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2020.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2020, filed 16 Feb 2021.